Sign in to continue:

Tuesday, March 10th, 2026

ENN Energy Holdings Limited Share Dealings Disclosure by UBS AG on 6 March 2026

Potential Price Sensitive Information for Shareholders

  • Privatisation Scheme: The ongoing privatisation of ENN Energy Holdings Limited is a major corporate event that could significantly impact the company’s share price and valuation. Investors should closely monitor developments related to this scheme.
  • Significant Institutional Activity: UBS AG’s purchase of a sizeable block of shares as part of its principal trading activities may reflect increased institutional interest or hedging activity in ENN Energy. While the purchases were executed in response to client-driven orders, the size and timing in the context of privatisation may be material for the market.
  • Consistent Pricing: All shares were transacted at the same price, which could provide a benchmark for current market valuation during this sensitive period.
  • Hedging Activity vs. Strategic Buying: The report clarifies that the dealings were for hedging purposes, not strategic accumulation; however, the involvement of a major institutional player like UBS AG can influence market sentiment.

Detailed Transaction Summary

Party Date Description Nature of Dealings Purchase/Sale Number of Shares Total Amount Price (Highest/Lowest)
UBS AG 6 March 2026 Ordinary Shares – Hedging of Delta 1 products (client-driven, unsolicited) Hedging Purchase 24,800 \$1,706,169.99 \$68.7972 / \$68.7972

What Should Shareholders Do?

  • Remain vigilant for further announcements regarding the privatisation process, as it could materially affect the company’s future and share price.
  • Monitor institutional activity and disclosures, as these may signal shifts in market expectations.
  • Consider the price at which UBS AG transacted when evaluating your own trading decisions, especially if you are a short-term investor.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence or consult a financial advisor before making investment decisions. All information is based on the latest public disclosure and may be subject to change.

View ENN ENERGY Historical chart here



Sino Biopharmaceutical and Sanofi Sign Global Exclusive License Agreement for ROVADICITINIB, a First-in-Class JAK/ROCK Inhibitor 12

Sino Biopharm Signs Major Global License Deal with Sanofi for Rovadicitinib Sino Biopharm Signs Major Global License Deal with Sanofi for Rovadicitinib Key Points from the Announcement Sino Biopharmaceutical Limited (Stock code: 1177) has...

Public Disclosure of Securities Dealings in ENN Natural Gas Co., Ltd. by Morgan Stanley & Co. International plc – 26 February 2026 1

Disclosure of Dealings in ENN Natural Gas Co., Ltd. Shares by Morgan Stanley & Co., International plc Key Developments in ENN Natural Gas Co., Ltd.: Morgan Stanley’s Share Dealings Disclosed Summary of the Disclosure...

Sihuan Pharmaceutical’s Bireociclib (Xuanyuening) Receives NMPA Approval for First-Line HR+/HER2- Advanced Breast Cancer Treatment in China

Sihuan Pharmaceutical: Key Milestone in Breast Cancer Drug Approval Sihuan Pharmaceutical Achieves Landmark Drug Approval for Advanced Breast Cancer Treatment Key Highlights Marketing Approval Granted for Xuanyuening (Bireociclib Tablets) Third Indication: The National Medical...

   Ad